Nanobiotix SA logo

Nanobiotix SA

NBTX
Healthcare|Biotechnology|France
$39.95
+1.12 (+2.88%)

Analyst Estimates

annual
{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 56.89, 86.49, 87.2, 97.6, 159.28 ], "ebit_estimate": [ 12.44, 27.95, 12.17, 20.98, 66.86 ], "ebitda_estimate": [ -15.04, 43.35, null, null, null ], "net_income_estimate": [ -1.75, 20.75, 8.59, 10.84, 52.24 ], "per_share_eps_estimate": [ 0.05, -0.01, 0.18, -0.19, -0.07 ], "eps_nri_estimate": [ -0.34, 0.04, -0.14, 0.17, 0.92 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 0.27, -0.08, -0.98, null, null ], "pretax_income_estimate": [ 8.21, 7.38, 13.83, 10.96, 58.08 ], "operating_cash_flow_per_share_estimate": [ 0.74, -0.1, -0.29, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -45.47, -456.1, -6.35, null, null ], "gross_margin_estimate": [ 100, 100, 99.35, 94, 93 ], "operating_cash_flow_estimate": [ 35.72, -4.95, -14.08, null, null ], "pettm_estimate": [ 832.29, 0, 228.29, 0, 0 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "58.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 58, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }
quarterly
{ "date": [ "202606", "202612" ], "revenue_estimate": [ null, null ], "ebit_estimate": [ null, null ], "ebitda_estimate": [ null, null ], "net_income_estimate": [ null, null ], "per_share_eps_estimate": [ null, null ], "eps_nri_estimate": [ -0.12, -0.12 ], "dividend_estimate": [ null, null ], "book_value_per_share_estimate": [ null, null ], "pretax_income_estimate": [ null, null ], "operating_cash_flow_per_share_estimate": [ null, null ], "roa_estimate": [ null, null ], "roe_estimate": [ null, null ], "gross_margin_estimate": [ null, null ], "operating_cash_flow_estimate": [ null, null ], "pettm_estimate": [ null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "58.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 58, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }